Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein
- 1 October 1999
- journal article
- Published by Springer Nature in Nature Genetics
- Vol. 23 (2) , 222-227
- https://doi.org/10.1038/13854
Abstract
Chromosomal translocations resulting in the expression of chimaeric transcription factors are frequently observed in tumour cells, and have been suggested to be a common mechanism in human carcinogenesis. Ewing sarcoma and related peripheral primitive neuroectodermal tumours share recurrent translocations that fuse the gene EWSR1 (formerly EWS) from 22q-12 to FLI1 and genes encoding other ETS transcription factors (which bind DNA through the conserved ETS domain). It has been shown that transduction of the gene EWSR1-FLI1 (encoding EWS-FLI1 protein) can transform NIH3T3 cells, and that mutants containing a deletion in either the EWS domain or the DNA-binding domain in FLI1 lose this ability. This indicates that the EWS-FLI1 fusion protein may act as an aberrant transcription factor, but the exact mechanism of oncogenesis remains unknown. Because ETS transcription factors regulate expression of TGFBR2 (encoding the TGF-beta type II receptor, TGF-beta RII; Refs 9,14), a putative tumour suppressor gene, we hypothesized that TGFBR2 may be a target of the EWS-FLI1 fusion protein. We show here that Ewing sarcoma [corrected] (ES) cell lines with the EWSR1-FLI1 fusion have reduced TGF-beta sensitivity, and that fusion-positive ES cells and primary tumours both express low or undetectable levels of TGFBR2 mRNA and protein product. Co-transfection of FLI1 and the TGFBR2 promoter induces promoter activity, whereas EWSR1-FLI1 leads to suppression of TGFBR2 promoter activity and FLI1-induced promoter activity. Introduction of EWSR1-FLI1 into cells lacking the EWSR1-FLI1 fusion suppresses TGF-beta RII expression, whereas antisense to EWSR1-FLI1 in ES cell lines positive for this gene fusion restores TGF-beta RII expression. Furthermore, introduction of normal TGF-beta RII into ES cell lines restores TGF-beta sensitivity and blocks tumorigenicity. Our results implicate TGF-beta RII as a direct target of EWS-FLI1.Keywords
This publication has 17 references indexed in Scilit:
- A Novel ets-related Transcription Factor, ERT/ESX/ESE-1, Regulates Expression of the Transforming Growth Factor-β Type II ReceptorPublished by Elsevier ,1998
- EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenicNature Genetics, 1997
- Isolation and Characterization of a Novel Epithelium-Specific Transcription Factor, ESE-1, a Member of the ets FamilyMolecular and Cellular Biology, 1997
- ESX: a structurally unique Ets overexpressed early during human breast tumorigenesisOncogene, 1997
- Identification of Target Genes for the Ewing's Sarcoma EWS/FLI Fusion Protein by Representational Difference AnalysisMolecular and Cellular Biology, 1995
- Chromosomal translocations in human cancerNature, 1994
- DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma.Molecular and Cellular Biology, 1994
- A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERGNature Genetics, 1994
- Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.Proceedings of the National Academy of Sciences, 1993
- Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumoursNature, 1992